Efficacy, safety, and prognostic modeling in neoadjuvant immunotherapy for esophageal squamous cell carcinoma
Pathological staging combined with albumin level and systemic immune-inflammation index could be a superior predictor of survival prognosis in ESCC patients receiving neoadjuvant immunotherapy. The findings of this study yield new evidence regarding the efficacy and safety of neoadjuvant immunotherapy in ESCC and provide a tool for identifying patients at risk of recurrence.
Authors
- Gaojie Xin
- Quanchao Sun
- Naicheng Song
- Zhaokai Wang (ORCID: https://orcid.org/0009-0007-4357-7802)
- Zhihong Huang (ORCID: https://orcid.org/0000-0002-3913-1177)
- Ai Huang (ORCID: https://orcid.org/0000-0001-7796-5343)
- Yongde Liao (ORCID: https://orcid.org/0000-0001-7989-2969)
- Ke Jiang (ORCID: https://orcid.org/0000-0002-8077-5951)
- Shijie Xing (ORCID: https://orcid.org/0000-0001-9733-3407)
- Huan Zhang (ORCID: https://orcid.org/0000-0003-0060-9169)
- Zuhuan Yao
- Yue Qu
Institutions
- Union Hospital (HK)
- Wuhan Union Hospital (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1016/j.intimp.2024.112845
- Citations
- 6
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.44